产超广谱β-内酰胺酶(ESBLs)大肠埃希氏菌的耐药调查及用药分析  

Drug Resistance and Medication Analysis of ESBLs-Producing Escherichia Coli in the Hospital

作　　者：罗石任[1] 王锦爱[1] 张云芳[1] 

机构地区：[1]洛阳正骨医院,河南洛阳471002

出　　处：《亚太传统医药》2014年第24期128-130,共3页Asia-Pacific Traditional Medicine

摘　　要：目的:观察产超广谱β-内酰胺酶(ESBLs)大肠埃希氏菌的耐药特征及抗感染用药现状。方法:对43株产ESBLs大肠埃希氏菌进行耐药率统计和抗感染用药的回顾性分析。结果:产ESBLs大肠埃希氏菌对亚胺培南、美罗培能等敏感率均为100%,对其它抗菌药物耐药情况较为严重。43株产ESBLs大肠埃希氏菌感染病例中,单用抗菌药物25例,联用抗菌药物15例,未选用抗菌药物3例,其中最常用药物为头孢西丁。结论:ESBLs菌株给临床抗菌治疗带来了较大困难,因此临床医师及药学人员应对其有充分认识,合理使用抗菌药物,减少产ESBLs大肠埃希氏菌的出现和传播。Studying the patients infected ESBLs-Producing about the condition resisted drug and the condition of drug a- gainst infection. Methods：Bacterial drug resistance of 43 stains of ESBLs Producing Eseherichia coli and the application of antibiot ics were analyzed retrospectieely. Results ： Imipenem and meropenem the susceptive rates for ESBLs-Producing Escherlchia eoli are 100 % ;other antibiotic is seriously resisted drug. In the fourty-three cases infected ESBLs-Producing E. coil, twenty five of them are treated with one antibiotic . fifteen of them is is treated with Combined with antibiotics. , three of them is not treated with antibiotic. Which were treated empirically predominantly with Cefoxitin. Conclusion ： ESBLs-Producing Eseheriehia coli make a series of diffi- culties in clinical eherapy with antibiotics , therefore clinicians and pharmacists should have full understanding of it , rational use of antimicrobial agents, reduce the occurrence of ESBLs producing Escherichia coil and spread.

关 键 词：超广谱β-内酰胺酶 大肠埃希氏菌 耐药特征 用药分析 

分 类 号：R446.5[医药卫生—诊断学]